Status and phase
Conditions
Treatments
About
This is an open-label, single-arm study with dose-escalation and expansion phases to access ATG-008 combined with Toripalimab in patients with advanced solid tumors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Know and voluntarily sign informed consent.
Age 18-70 years old (including 18 and 70 years old), weight ≥45 Kg.
At least one measurable lesion according to the RECIST 1.1 and RANO evaluation criteria.
ECOG performance status score is 0 or 1.
Blood chemistry test results, meet the following results:
Adequate bone marrow function and meets the following results:
Except for hearing loss and hair loss, all toxicity caused by previous anti-tumor therapy must have returned to ≤ Grade 1 (according to NCI-CTCAE version 5.0).
Life expectancy is longer than 3 months.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
60 participants in 1 patient group
Loading...
Central trial contact
Li Zheng
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal